Clinical Trials Logo

Splenic Thrombosis clinical trials

View clinical trials related to Splenic Thrombosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02585713 Completed - Pulmonary Embolism Clinical Trials

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Start date: November 20, 2015
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE